I work with a law firm investigating reports of possible securities law violations by Matrixx Initiatives, Inc., the maker of Zicam.
In a letter to Matrixx, the FDA concluded certain Zicam products may pose serious risks to consumers.
When the letter was released, Matrixx stock plummeted from approximately $19 per share to less than $7 per share. Since December 2007, insiders have sold more than $2.7 million worth of Matrixx shares.
Market Data 
Markets 
AI
